BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

899 related articles for article (PubMed ID: 9483160)

  • 1. Neonatal screening for inborn errors of metabolism: cost, yield and outcome.
    Pollitt RJ; Green A; McCabe CJ; Booth A; Cooper NJ; Leonard JV; Nicholl J; Nicholson P; Tunaley JR; Virdi NK
    Health Technol Assess; 1997; 1(7):i-iv, 1-202. PubMed ID: 9483160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review.
    Pandor A; Eastham J; Beverley C; Chilcott J; Paisley S
    Health Technol Assess; 2004 Mar; 8(12):iii, 1-121. PubMed ID: 14982654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of expanding newborn screening for up to 21 inherited metabolic disorders using tandem mass spectrometry: results from a decision-analytic model.
    Cipriano LE; Rupar CA; Zaric GS
    Value Health; 2007; 10(2):83-97. PubMed ID: 17391418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Newborn screening for inborn errors of metabolism: a systematic review.
    Seymour CA; Thomason MJ; Chalmers RA; Addison GM; Bain MD; Cockburn F; Littlejohns P; Lord J; Wilcox AH
    Health Technol Assess; 1997; 1(11):i-iv, 1-95. PubMed ID: 9483156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Economic Evaluation of Neonatal Screening for Inborn Errors of Metabolism Using Tandem Mass Spectrometry in Thailand.
    Thiboonboon K; Leelahavarong P; Wattanasirichaigoon D; Vatanavicharn N; Wasant P; Shotelersuk V; Pangkanon S; Kuptanon C; Chaisomchit S; Teerawattananon Y
    PLoS One; 2015; 10(8):e0134782. PubMed ID: 26258410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-benefit analysis: newborn screening for inborn errors of metabolism in Lebanon.
    Khneisser I; Adib S; Assaad S; Megarbane A; Karam P
    J Med Screen; 2015 Dec; 22(4):182-6. PubMed ID: 26062758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A critical review of the role of neonatal hearing screening in the detection of congenital hearing impairment.
    Davis A; Bamford J; Wilson I; Ramkalawan T; Forshaw M; Wright S
    Health Technol Assess; 1997; 1(10):i-iv, 1-176. PubMed ID: 9483157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inborn errors of metabolism and expanded newborn screening: review and update.
    Mak CM; Lee HC; Chan AY; Lam CW
    Crit Rev Clin Lab Sci; 2013 Nov; 50(6):142-62. PubMed ID: 24295058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expanding screening for rare metabolic disease in the newborn: an analysis of costs, effect and ethical consequences for decision-making in Finland.
    Autti-Rämö I; Mäkelä M; Sintonen H; Koskinen H; Laajalahti L; Halila R; Kääriäinen H; Lapatto R; Näntö-Salonen K; Pulkki K; Renlund M; Salo M; Tyni T
    Acta Paediatr; 2005 Aug; 94(8):1126-36. PubMed ID: 16188860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening newborns for inborn errors of metabolism by tandem mass spectrometry.
    Wilcken B; Wiley V; Hammond J; Carpenter K
    N Engl J Med; 2003 Jun; 348(23):2304-12. PubMed ID: 12788994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Expanded newborn screening in the Region of Murcia, Spain. Three-years experience].
    Juan-Fita MJ; Egea-Mellado JM; González-Gallego I; Moya-Quiles MR; Fernández-Sánchez A
    Med Clin (Barc); 2012 Dec; 139(13):566-71. PubMed ID: 22137990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Newborn screening by tandem mass spectrometry for medium-chain Acyl-CoA dehydrogenase deficiency: a cost-effectiveness analysis.
    Venditti LN; Venditti CP; Berry GT; Kaplan PB; Kaye EM; Glick H; Stanley CA
    Pediatrics; 2003 Nov; 112(5):1005-15. PubMed ID: 14595039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of tandem mass spectrometry newborn screening in Australia.
    Norman R; Haas M; Chaplin M; Joy P; Wilcken B
    Pediatrics; 2009 Feb; 123(2):451-7. PubMed ID: 19171609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of neonatal screening for Duchenne muscular dystrophy--how does this compare to existing neonatal screening for metabolic disorders?
    Rosenberg T; Jacobs HK; Thompson R; Horne JM
    Soc Sci Med; 1993 Aug; 37(4):541-7. PubMed ID: 8211266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economics of tandem mass spectrometry screening of neonatal inherited disorders.
    Pandor A; Eastham J; Chilcott J; Paisley S; Beverley C
    Int J Technol Assess Health Care; 2006; 22(3):321-6. PubMed ID: 16984060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Newborn screening for congenital heart defects: a systematic review and cost-effectiveness analysis.
    Knowles R; Griebsch I; Dezateux C; Brown J; Bull C; Wren C
    Health Technol Assess; 2005 Nov; 9(44):1-152, iii-iv. PubMed ID: 16297355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulse oximetry as a screening test for congenital heart defects in newborn infants: a test accuracy study with evaluation of acceptability and cost-effectiveness.
    Ewer AK; Furmston AT; Middleton LJ; Deeks JJ; Daniels JP; Pattison HM; Powell R; Roberts TE; Barton P; Auguste P; Bhoyar A; Thangaratinam S; Tonks AM; Satodia P; Deshpande S; Kumararatne B; Sivakumar S; Mupanemunda R; Khan KS
    Health Technol Assess; 2012; 16(2):v-xiii, 1-184. PubMed ID: 22284744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and outcome of expanded newborn screening for metabolic diseases--report of 10 years from South-West Germany.
    Lindner M; Gramer G; Haege G; Fang-Hoffmann J; Schwab KO; Tacke U; Trefz FK; Mengel E; Wendel U; Leichsenring M; Burgard P; Hoffmann GF
    Orphanet J Rare Dis; 2011 Jun; 6():44. PubMed ID: 21689452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-benefit analysis of universal tandem mass spectrometry for newborn screening.
    Schoen EJ; Baker JC; Colby CJ; To TT
    Pediatrics; 2002 Oct; 110(4):781-6. PubMed ID: 12359795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation of the usefulness for neonatal mass screening in light of 35 years personal experience].
    Bozkowa K; Cabalska B; Radomyska B; Ołtarzewski M; Lenartowska I
    Med Wieku Rozwoj; 1999; 3(4):529-59. PubMed ID: 10910678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.